Bimakalim: A promising K(ATP) channel activating agent

Cardiovascular Drug Reviews

Volumn 18, Issue 1, 2000, Pages 25-46

  Puddu, Paolo Emilio ^a   Garlid, Keith D ^b   Monti, Francesco ^a   Iwashiro, Katsunori ^a   Picard, Sandra ^c   Dawodu, Amos Adeyemo ^a   Criniti, Anna ^a   Ruvolo, Giovanni ^a   Campa, Pietro Paolo ^a  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c UNIVERSITÉ DE CAEN   (France)

Author keywords

ATP dependent potassium channels; Bimakalim; Contractility; Electrophysiology; Myocardial protection

Indexed keywords

APRIKALIM; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BIMAKALIM; CROMAKALIM; DOBUTAMINE; EMAKALIM; FELODIPINE; GLIBENCLAMIDE; NICORANDIL; PINACIDIL; POTASSIUM CHANNEL; POTASSIUM CHANNEL BLOCKING AGENT; POTASSIUM CHANNEL STIMULATING AGENT; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR EFFECT; CORONARY ARTERY BLOOD FLOW; DRUG EFFECT; HEART PROTECTION; HUMAN; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0034077543     PISSN: 08975957     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2000.tb00031.x     Document Type: Review

References (62)

1. + Channels in cardiovascular medicine. Paris: Springer-Verlag, 1993;161-174.
2. Auchampach JA, Gross GJ. Reduction in myocardial infarct size by the new potassium channel opener bimakalim. J Cardiovasc Pharmacol 1994;23:554-561.
3. ATP channel. Circulation 1997;95:1278-1285.
4. + Channels in cardiovascular medicine. Paris: Springer-Verlag, 1993;293-303.
5. + Channels in cardiovascular medicine. Paris: Springer-Verlag, 1993;69-91.
6. Bril A, Man RYK. Effects of the potassium channel activator, BRL 34915, on the action potential characteristics of canine cardiac Purkinje fibers. J Pharmacol Exp Ther 1990;253:1090-1096.
7. + Channels in cardiovascular medicine. Paris: Springer-Verlag, 1993;193-223.
8. Cavero I, Premmereur J. ATP sensitive potassium channel openers are of potential benefit in ischaemic heart disease. Cardiovasc Res 1994;28:32-33.
9. + channels protect the myocardium against ischemia/reperfusion damage. Circ Res 1991;69:571-581.
10. Damiano RJ. The electrophysiology of ischemia and cardioplegia: Implications for myocardial protection. J Card Surg 1995;10:445-453.
11. De Mey C, Erb K, Schroeter V, Belz GG. Differentiation of inodilatory responses by non-invasive measures of cardiovascular performance in healthy man. Int J Clin Pharmacol Ther 1996;34:525-532.
12. + channel activator, EMD 52692, in electrophysiological and pharmacological experiments. Pflugers Arch 1989;414(Suppl 1):S191.
13. Dorman BH, Cavallo MJ, Hinton RB, Roy RC, Spinale FG. Preservation of myocyte contractile function after hypothermic, hyperkalemic cardioplegic arrest with 2,3-butanedione monoxime. J Thorac Cardiovasc Surg 1996;111:621-629.
14. + channel openers and "natural" cardioprotection. Trends Pharmacol Sci 1992;13:269-272.
15. + Channels in cardiovascular medicine. Paris: Springer-Verlag, 1993;225-244.
16. + channels. J Biol Chem 1988;263:7933-7936.
17. + channels. Possible mechanism of cardioprotection. Circ Res 1997;81:1072-1082.
18. ATP channel as a receptor for potassium channel openers. J Biol Chem 1996;271:8796-8799.
19. Gautier P, Bertrand JP, Guiraudou P. Effects of SR 44866, a potassium channel opener, on action potentials of rabbit, guinea pig, and human heart fibers. J Cardiovasc Pharmacol 1991;17:692-700.
20. Gericke R, Lues I, de Peyer JE, Haeusler G. Electrophysiological and pharmacological characterization of EMD 52692, a new potassium channel activator. Naunyn-Schmiedeberg's Arch Pharmacol 1989;339:R62.
21. + channels: Pharmacologic properties, regulation, and therapeutic potential. Drug Develop Res 1993;28:95-127.
22. Gross GJ, Auchampach JA, Maruyama M, Warltier DC, Pieper GM. Cardioprotective effects of nicorandil. J Cardiovasc Pharmacol 1992;20(Suppl 3):S22-S28.
23. + channels and myocardial preconditioning. Circ Res 1999;84:973-979.
24. 1 receptor blockade does not abolish the cardioprotective effects of the adenosine triphosphate-sensitive potassium channel opener bimakalim. J Pharmacol Exp Ther 1997;280:533-540.
25. ATP) openers in models of myocardial ischemia and reperfusion. J Physiol Pharmacol 1997;75:309-315.
26. Grover GJ, D'Alonzo AJ, Hess T, Sleph PG, Darbenzio RB. Glyburide-reversible cardioprotective effects of BMS-180448 is independent of action potential shortening. Cardiovasc Res 1995;30:731-738.
27. Haverkamp W, Borggrefe M, Breithardt G. Electrophysiologic effects of potassium channel openers. Cardiovasc Drugs Ther 1995;9:195-202.
28. Hearse DJ. Activation of ATP-sensitive potassium channels: A novel pharmacological approach to myocardial protection? Cardiovasc Res 1995;30:1-17.
29. + channels modulate cardiac mitochondrial function. Am J Physiol 1998;275:H1567-H1576.
30. ATP channels. Mol Pharmacol 1999;55:1000-1005.
31. Iwashiro K, Criniti A, Sinatra R, et al. Felodipine protects human atrial muscle from hypoxia-reoxygenation dysfunction: A force-frequency relationship study in an in vitro model of stunning. Int J Cardiol 1997;62:107-132.
32. ATP channel by glyburide and 5-hydroxydecanoate. J Biol Chem 1998;273:13578-13582.
33. max by lidocaine but not by disopyramide in guinea-pig papillary muscles. Naunyn-Schmiedebergs Arch Pharmacol 1988;337:203-212.
34. + Channels in cardiovascular medicine. Paris: Springer-Verlag, 1993;285-291.
35. ATP channel agonist bimakalim in isolated guinea pig ventricular muscle. Gen Pharmacol 1998;31:125-131.
36. McCullough JR, Normandin DE, Conder ML, Sleph PG, Dzwonczyk S, Grover GJ. Specific block of the anti-ischemic actions of cromakalim by sodium 5-hydroxydecanoate. Circ Res 1991;69:949-958.
37. ATP channel opener: Effects on interstitial adenosine in dogs. J Mol Cell Cardiol 1998;30:1225-1236.
38. Mizurnura T, Nithipatikom K, Gross GJ. Bimakalim, an ATP-sensitive potassium channel opener, mimics the effects of ischemic preconditioning to reduce infarct size, adenosine release, and neutrophil function in dogs. Circulation 1995;92:1236-1245.
39. + channel blockers on the action potential shortening in hypoxic and ischaemic myocardium. Br J Pharmacol 1991;103:1019-1026.
40. Nichols CG, Ripoll C, Lederer WJ. ATP-sensitive potassium channel modulation of the guinea pig ventricular action potential and contraction. Circ Res 1991;68:280-287.
41. + channel from rat liver and beef heart mitochondria. J Biol Chem 1992;267:26062-26069.
42. ATP activation with low concentrations of bimakalim. J Cardiovasc Pharmacol 1999;34:162-172.
43. ATP channels and 'border zone' arrhythmias: Role of the repolarization dispersion between normal and ischaemic ventricular regions. Br J Pharmacol 1999;127:1687-1695.
44. + channel modulator aprikalim (RP 52891): Improved cardioprotection in isolated ischemic rabbit hearts. Can J Physiol Pharmacol 1994;72:126-132.
45. Qiu Y, Galinanes M, Hearse DJ. Protective effect of nicorandil as an additive to the solution for continuous warm cardioplegia. J Thorac Cardiovasc Surg 1995;110:1063-1072.
46. Rohmann S, Weygandt H, Schelling P, et al. Effect of bimakalim (EMD 52692), an opener of ATP sensitive potassium channels, on infarct size, coronary blood flow, regional wall function, and oxygen consumption in swine. Cardiovasc Res 1994;28:858-863.
47. Rossi A, Kay L, Saks VA. Early ischemia-induced alterations of the outer mitochondrial membrane and the intermembrane space: A potential cause for altered energy transfer in cardiac muscle? Mol Cell Biochem 1998;184:401-408.
48. Rouet R, Picard S, Criniti A, et al. Effects of bimakalim on human cardiac action potentials: Comparison with guinea pig and nicorandil and use-dependent study. J Cardiovasc Pharmacol 1999;33:255-263.
49. Saks VA, Dos Santos P, Gellerich FN, Diolez P. Quantitative studies of enzyme-substrate compartmentation, functional coupling and metabolic channeling in muscle cells. Mol Cell Biochem 1998;184:291-307.
50. Saks VA, Veksler VI, Kuznetsov AV, et al. Permeabilized cell and skinned fiber techniques in studies of mitochondrial function in vivo. Mol Cell Biochem 1998;184:81-100.
51. Sassen LM, Duncker DJ, Gho BC, Diekmann HW, Verdouw PD. Haemodynamic profile of the potassium channel activator EMD 52692 in anaesthetized pigs. Br J Pharmacol 1990;101:605-614.
52. Senior R, Buchner-Moell D, Raftery E, Lahiri A. Potent hemodynamic effects of bimakalim, a new potassium channel opener, in humans. J Cardiovasc Pharmacol 1993;22:717-721.
53. Stowe DF, Graf BM, Fupta S, Gross GJ. One-day cold perfusion of bimakalim and butanedione monoxime restores ex situ cardiac function. Am J Physiol 1996;271:H1884-H1892.
54. + channels enhances myocardial protection due to cold high potassium cardioplegia: A force-frequency relationship study. J Mol Cell Cardiol 1995;27:1867-1881.
55. Sugimoto S, Puddu PE, Monti F, Schiariti M, Campa PP, Marino B. Pretreatment with the adenosine triphosphate-sensitive potassium channel opener nicorandil and improved myocardial protection during high-potassium cardioplegic hypoxia. J Thorac Cardiovasc Surg 1994;108:455-466.
56. Tomai F, Crea F, Chiariello L, Gioffrè PA. Ischemic preconditioning in humans: models, mediators, and clinical relevance. Circulation 1999;100:559-563.
57. van Woerkens EJ, Baas NRA, van der Giessen WJ, Verdouw PD. Cardiovascular effects of the novel potassium channel opener bimakalim in conscious pigs after myocardial infarction: a comparative study with nicorandil. Cardiovasc Drugs Ther 1992;6:409-417.
58. Williams AJ. Potassium channel openers: Clinical aspects. In: Weston AH, Hamilton TC, eds. Potassium Channel Modulators: Pharmacological, Molecular and Clinical Aspects. Oxford: Blackwell Scientific Publications, 1992;486-501.
59. ATP channels: An endogenous protective mechanism during repetitive ischemia. Am J Physiol 1993;264:H495-H504.
60. ATP channel opener bimakalim on coronary blood flow, monophasic action potential duration, and infarct size in dogs. Circulation 1994; 89: 1769-1775.
61. Yao Z, Gross GJ. Activation of ATP-sensitive potassium channels lowers threshold for ischemic preconditioning in dogs. Am J Physiol 1994;267:H1888-H1894.
62. ATP channels. Am J Physiol 1997;272:H334-H342.